Phase 2
Completed N=3
Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product
Scalp Psoriasis
Source: ClinicalTrials.gov NCT02933502 ↗
Enrolled (actual)
3
Serious AEs
0.0%
Results posted
Dec 2018
Primary outcomePrimary: Number of Participants With HPA Axis Suppression — 0; 2 Participants
Summary
An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With HPA Axis Suppression |
0; 2 | — |
Eligibility Criteria
Inclusion Criteria
- Male or non-pregnant, non-lactating females 12-17 years of age.
Exclusion Criteria
- Females who are pregnant, nursing, planning to become pregnant during the duration of the study, or if of child-bearing potential and sexually active and not prepared to use appropriate contraceptive methods to avoid pregnancy.
Data sourced from ClinicalTrials.gov (NCT02933502). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.